Licorice Botanical Dietary Supplements - Metabolism and Safety in Women

NCT ID: NCT03948243

Last Updated: 2023-05-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-04-01
• Study Completion Date: 2022-04-22

Brief Summary

Human safety studies will be carried out to test whether red clover botanical dietary supplements used by peri- and post-menopausal women are safe to use with Food and Drug Administration (FDA)-approved drugs. To test this, a red clover dietary supplement (previously tested in women at the University of Illinois at Chicago without any harmful effects) will be given with four selected FDA-approved drugs to determine if the Licorice supplement can increase or decrease how these medications are absorbed, metabolized and excreted by the human body. Preclinical studies predict that the licorice supplement might affect the metabolism or break down of these probe drugs.

Detailed Description

At the start of a study, subjects will be administered low doses of a mixture of four FDA-approved drugs (caffeine, tolbutamide, dextromethorphan, and alprazolam), and serial blood samples will be drawn and analyzed for the concentration of each drug over time. Afterwards, participants will take the licorice dietary supplement twice daily for 14 days to allow for potential inhibition or induction of drug metabolizing enzymes and transporters. Thereafter, the same drugs will be taken again to obtain a second measure of drug concentrations in blood over time. Changes in the concentration-time curve values for each probe drug obtained before and after ingestion of the supplement would indicate that metabolism of the probe drugs is impacted by the licorice dietary supplement.

Conditions

Food-drug Interaction

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

G.Glabra

single arm

Group Type: EXPERIMENTAL

Licorice

Intervention Type: DIETARY_SUPPLEMENT

Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days

Alprazolam 2 MG

Intervention Type: DRUG

probe substrate

Caffeine 100 MG

Intervention Type: DRUG

probe substrate

Tolbutamide 250 mg

Intervention Type: DRUG

probe substrate

Dextromethorphan 30mg

Intervention Type: DRUG

probe substrate

Interventions

Licorice

Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days

Intervention Type: DIETARY_SUPPLEMENT

Alprazolam 2 MG

probe substrate

Intervention Type: DRUG

Caffeine 100 MG

probe substrate

Intervention Type: DRUG

Tolbutamide 250 mg

probe substrate

Intervention Type: DRUG

Dextromethorphan 30mg

probe substrate

Intervention Type: DRUG

Other Intervention Names

G. glabra; CYP3A4/5 substrate; CYP1A2 substrate; CYP2C9 substrate; CYP2D6 substrate

Eligibility Criteria

Inclusion Criteria

• healthy peri- and post-menopausal women ages 40 - 79
• non-smokers
• no-significant medical conditions as assessed by subject-reported medical history, physical examination and blood and urine chemistry screens
• no medical condition that requires chronic use of medication

Exclusion Criteria

• known allergies or hypersensitivity to caffeine, dextromethorphan, sulfonylureas (tolbutamide), benzodiazepines, or licorice
• positive pregnancy test
• use of hormone therapy within 8 weeks of study initiation for oral agents, 4 weeks for transdermal or other topical agents
• use of caffeine products 7 days before study participation or during the study
• use of citrus products 7 days before study participation or during the study
• other prescription (with the exception of the Mirena® IUD) or non-prescription medicines within the 2 weeks prior to study initiation or during the study
• chronic diseases, such as inflammatory bowel disease, that could alter the absorption or metabolism of the probe substrates
• unwillingness to comply with study requirements
• current participation in another clinical trial
• CYP2D6 deficiency based on phenotyping at screening
• smoker
• licorice (whether as a botanical dietary supplement, candy, food, drink or otherwise) within the previous two weeks and during the study
• use of any dietary supplements within the last 2 weeks prior to study initiation and during the study
• extreme obesity (defined as >40 BMI)
• alcohol or drug abuse
• chronic diseases such as diabetes.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Oregon State University

OTHER

Sponsor Role: collaborator

University of Illinois at Chicago

OTHER

Sponsor Role: lead

Responsible Party

Richard B van Breemen

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Richard vanBreemen, PhD

Role: STUDY_DIRECTOR

University of Illinois at Chicago

Locations

University of Illinois at Chicago

Chicago, Illinois, United States

Countries

United States

Other Identifiers

2019-0115

Identifier Type: -

Identifier Source: org_study_id